Kyverna Therapeutics Reports $39.7M Net Loss in Q1 2026, Decreases Operating Expenses

Kyverna Therapeutics, Inc. reported a net loss of $39.7 million for the first quarter of 2026, a decrease from the $44.6 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $41.4 million, down 13% from $47.4 million year-over-year. This reduction was primarily driven by a 20% decrease in research and development expenses, which fell to $30.1 million from $37.4 million, largely due to lower costs associated with contract manufacturing organizations (CMOs) as the company shifted focus from significant BLA readiness efforts in 2025.

Kyverna's cash and cash equivalents, along with available-for-sale marketable securities, totaled $236.4 million as of March 31, 2026, a decline from $282.9 million at the end of 2025. The company utilized $41.6 million in cash for operating activities during the quarter, slightly less than the $44.9 million used in the same period last year. The decrease in cash usage was attributed to a combination of lower net losses and changes in operating assets and liabilities, including a significant reduction in accrued compensation.

In terms of strategic developments, Kyverna is advancing its lead product candidate, mivocabtagene autoleucel (miv-cel), through late-stage clinical trials for autoimmune diseases, including stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). The company recently presented positive results from its Phase 2 clinical trial for miv-cel in SPS at the 2026 American Academy of Neurology Annual Meeting, demonstrating significant clinical benefits. Additionally, Kyverna has initiated a rolling Biologics License Application (BLA) submission for miv-cel in SPS, with expectations to complete the submission by the fourth quarter of 2026.

Operationally, Kyverna's employee headcount has increased, contributing to a rise in general and administrative expenses, which grew by 13% to $11.3 million. The company continues to strengthen its chemistry, manufacturing, and controls capabilities to support its clinical development and anticipated commercialization efforts. As of March 31, 2026, the company had 60.5 million shares outstanding, reflecting a slight increase from the previous quarter.

Looking ahead, Kyverna anticipates continued operating losses as it invests in the development of its product candidates and expands its research initiatives. The company plans to monitor expenses closely and may seek additional capital through equity or debt financing to support its operations. Management believes that its current cash reserves will be sufficient to fund operations for at least the next 12 months, but acknowledges the need for ongoing capital to sustain its development programs and achieve profitability in the future.